Physical Characterization and Innate Immunogenicity of Aggregated Intravenous Immunoglobulin (IGIV) in an In Vitro Cell-Based Model
|
journal
|
April 2016 |
Masking of endotoxin in surfactant samples: Effects on Limulus-based detection systems
|
journal
|
September 2016 |
Immunomodulatory activity of interferon‐beta
|
journal
|
July 2014 |
Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction
|
journal
|
February 2016 |
Cutting Edge: Repurification of Lipopolysaccharide Eliminates Signaling Through Both Human and Murine Toll-Like Receptor 2
|
journal
|
July 2000 |
Immunologic Therapy of Multiple Sclerosis
|
journal
|
February 1999 |
Pattern Recognition Receptors and Inflammation
|
journal
|
March 2010 |
Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory
|
journal
|
August 2002 |
Monocyte Activation Test (MAT) reliably detects pyrogens in parenteral formulations of human serum albumin [EN]
|
journal
|
January 2011 |
Cooperation of Toll-like receptor signals in innate immune defence
|
journal
|
March 2007 |
Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients
|
journal
|
February 2003 |
Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1–polarizing program in dendritic cells
|
journal
|
July 2005 |
Application of High Hydrostatic Pressure to Dissociate Aggregates and Refold Proteins
|
journal
|
June 2009 |
Managing uncertainty: A perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins
|
journal
|
October 2012 |
Frequency and Magnitude of Interferon β Neutralizing Antibodies in the Evaluation of Interferon β Immunogenicity in Patients with Multiple Sclerosis
|
journal
|
March 2011 |
TLR-based immune adjuvants
|
journal
|
April 2011 |
Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development
|
journal
|
September 2013 |
Impact of Product-Related Factors on Immunogenicity of Biotherapeutics
|
journal
|
February 2011 |
Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis
|
journal
|
April 2004 |
A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs
|
journal
|
May 2007 |
Immunogenicity of Recombinant Human Interferon Beta-1b in Immune-Tolerant Transgenic Mice Corresponds with the Biophysical Characteristics of Aggregates
|
journal
|
April 2016 |
Influence of Escherichia coli chaperone DnaK on protein immunogenicity
|
journal
|
December 2016 |
CD8 + T Cell Responses following Replication-Defective Adenovirus Serotype 5 Immunization Are Dependent on CD11c + Dendritic Cells but Show Redundancy in Their Requirement of TLR and Nucleotide-Binding Oligomerization Domain-Like Receptor Signaling
|
journal
|
July 2010 |
Beta-interferon for multiple sclerosis
|
journal
|
May 2011 |
Analytical techniques and bioactivity assays to compare the structure and function of filgrastim (granulocyte-colony stimulating factor) therapeutics from different manufacturers
|
journal
|
November 2013 |
Detection of Innate Immune Response Modulating Impurities in Therapeutic Proteins
|
journal
|
April 2015 |
An Albumin-Free Formulation for Escherichia coli -Derived Interferon Beta-1b with Decreased Immunogenicity in Immune Tolerant Mice
|
journal
|
March 2016 |
Application of the Limulus Test for Practical Quality Control on Endotoxin Content in Commercial Human Serum Albumin (HSA) Products. In Comparison with the Rabbit Pyrogen Test [ヒト血清アルブミン製剤中のエンドトキシン量の測定に対するリムルス試験の応用.ウサギ発熱試験との比較]
|
journal
|
January 1994 |
Use of human MonoMac6 cells for development of in vitro assay predictive of adjuvant safety in vivo
|
journal
|
July 2012 |
Endotoxin recovery using limulus amebocyte lysate (LAL) assay
|
journal
|
September 2016 |
Toll-like receptor 2 (TLR2) and dectin-1 contribute to the production of IL-12p40 by bone marrow-derived dendritic cells infected with Penicillium marneffei
|
journal
|
August 2008 |
New FDA Draft Guidance on Immunogenicity
|
journal
|
March 2014 |
Clinical Effect of Neutralizing Antibodies to Interferon Beta That Persist Long After Cessation of Therapy for Multiple Sclerosis
|
journal
|
April 2010 |
Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies
|
journal
|
July 2009 |
Aggregated Recombinant Human Interferon Beta Induces Antibodies but No Memory in Immune-Tolerant Transgenic Mice
|
journal
|
May 2010 |
The structure of human interferon- ? : implications for activity
|
journal
|
November 1998 |
Comparative Effects of Metal-Catalyzed Oxidizing Systems on Carbonylation and Integrity of Therapeutic Proteins
|
journal
|
October 2015 |
Characterization and Quantitation of Aggregates and Particles in Interferon-β Products: Potential Links Between Product Quality Attributes and Immunogenicity
|
journal
|
March 2013 |
Immunogenicity of Biotherapeutics—An Overview
|
journal
|
January 2006 |
Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis
|
journal
|
January 2004 |
Specific Immune Response to Phospholipase B-Like 2 Protein, a Host Cell Impurity in Lebrikizumab Clinical Material
|
journal
|
October 2016 |
In Vivo Effect of Innate Immune Response Modulating Impurities on the Skin Milieu Using a Macaque Model: Impact on Product Immunogenicity
|
journal
|
March 2017 |
CpG DNA Induces IgG Class Switch DNA Recombination by Activating Human B Cells through an Innate Pathway That Requires TLR9 and Cooperates with IL-10
|
journal
|
September 2004 |
Control of adaptive immunity by the innate immune system
|
journal
|
March 2015 |
Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells
|
journal
|
January 2003 |
Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates
|
journal
|
October 2003 |
Systemic Recombinant Human Interferon-β Treatment of Relapsing–Remitting Multiple Sclerosis: Pilot Study Analysis and Six-Year Follow-Up
|
journal
|
October 1993 |
Programming the magnitude and persistence of antibody responses with innate immunity
|
journal
|
February 2011 |
The role of glatiramer acetate in the early treatment of multiple sclerosis
|
journal
|
June 2010 |
Trace Levels of Innate Immune Response Modulating Impurities (IIRMIs) Synergize to Break Tolerance to Therapeutic Proteins
|
journal
|
December 2010 |
Evaluating Immunogenicity Risk Due to Host Cell Protein Impurities in Antibody-Based Biotherapeutics
|
journal
|
July 2016 |
Immunogenicity of An Interferon-β1a Product
|
journal
|
April 2011 |